# Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma

> clinical trial · VERIFIED · 2026-08-17

Status: ACTIVE_NOT_RECRUITING · Sponsor: National Cancer Institute (NCI) · Condition: Primary Central Nervous System Lymphoma

- Company: National Cancer Institute (NCI)
- Sector: oncology
- Primary source: https://clinicaltrials.gov/study/NCT02203526

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.